BR112016026581A2 - vetores de polietilenoimina polietilenoglicol melhorados - Google Patents
vetores de polietilenoimina polietilenoglicol melhoradosInfo
- Publication number
- BR112016026581A2 BR112016026581A2 BR112016026581A BR112016026581A BR112016026581A2 BR 112016026581 A2 BR112016026581 A2 BR 112016026581A2 BR 112016026581 A BR112016026581 A BR 112016026581A BR 112016026581 A BR112016026581 A BR 112016026581A BR 112016026581 A2 BR112016026581 A2 BR 112016026581A2
- Authority
- BR
- Brazil
- Prior art keywords
- polyethylene glycol
- vectors
- improved
- polyethyleneimine
- polyethyleneimine polyethylene
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 229920002873 Polyethylenimine Polymers 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
um poliplexo de um rna de filamento duplo e um conjugado polimérico é provido, em que o conjugado polimérico consiste em uma polietilenoimina linear covalentemente ligada a uma ou mais porções de polietilenoglicol (peg), cada porção de peg sendo conjugada via um ligante a uma porção alvo capaz de ligar-se a um antígeno de câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461993110P | 2014-05-14 | 2014-05-14 | |
PCT/IL2015/050514 WO2015173824A1 (en) | 2014-05-14 | 2015-05-14 | Improved polyethyleneimine polyethyleneglycol vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016026581A2 true BR112016026581A2 (pt) | 2017-10-31 |
Family
ID=54479412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016026581A BR112016026581A2 (pt) | 2014-05-14 | 2015-05-14 | vetores de polietilenoimina polietilenoglicol melhorados |
Country Status (17)
Country | Link |
---|---|
US (4) | US10278991B2 (pt) |
EP (1) | EP3142673A4 (pt) |
JP (3) | JP6753843B2 (pt) |
KR (2) | KR102472590B1 (pt) |
CN (3) | CN116966310A (pt) |
AU (2) | AU2015260725B2 (pt) |
BR (1) | BR112016026581A2 (pt) |
CA (1) | CA2949017A1 (pt) |
IL (2) | IL287206B2 (pt) |
MA (1) | MA39970A (pt) |
MX (2) | MX2016014881A (pt) |
NZ (1) | NZ727092A (pt) |
PH (1) | PH12016502258A1 (pt) |
RU (1) | RU2771104C2 (pt) |
SG (2) | SG10201911695SA (pt) |
WO (1) | WO2015173824A1 (pt) |
ZA (1) | ZA201608042B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2771104C2 (ru) * | 2014-05-14 | 2022-04-26 | Таргиммьюн Терапьютикс Аг | Улучшенные полиэтилениминовые полиэтиленгликолевые векторы |
PT3319587T (pt) * | 2015-11-17 | 2019-11-20 | Bioncotech Therapeutics S L | Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina |
KR102372857B1 (ko) * | 2016-03-07 | 2022-03-11 | 한미약품 주식회사 | 폴리에틸렌 글리콜 유도체 및 이의 용도 |
US11912747B2 (en) | 2016-09-04 | 2024-02-27 | Targimmune Therapeutics Ag | Chimeric proteins for targeting dsRNA |
CN110831581A (zh) | 2017-05-17 | 2020-02-21 | 拜昂科技医疗公司 | 包含具有双链多核糖核苷酸和聚乙烯亚胺的复合物的粒子的新型药物组合物 |
CN111164093A (zh) * | 2017-09-27 | 2020-05-15 | 塔尔格免疫治疗有限公司 | 去势抵抗性前列腺癌 |
EP3762417A1 (en) * | 2018-03-08 | 2021-01-13 | TargImmune Therapeutics AG | A recombinant protein comprising a double stranded rna binding domain |
CN109893657B (zh) * | 2019-02-28 | 2022-04-29 | 中国人民解放军军事科学院军事医学研究院 | 基因递送载体、药物复合物、抗肺纤维化药物及应用 |
KR20210146952A (ko) | 2019-04-03 | 2021-12-06 | 타르그이뮨 테라퓨틱스 아게 | 암의 치료를 위한 면역요법 |
WO2020263782A1 (en) * | 2019-06-24 | 2020-12-30 | North Carolina State University | Methods and compositions for modifying nucleic acids and for killing cells |
WO2021001023A1 (en) * | 2019-07-02 | 2021-01-07 | Biontech Rna Pharmaceuticals Gmbh | Rna formulations suitable for therapy |
MX2023004101A (es) | 2020-10-08 | 2023-10-11 | Targimmune Therapeutics Ag | Inmunoterapia para el tratamiento de cancer. |
CA3237153A1 (en) | 2021-11-05 | 2023-05-11 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
US20240091348A1 (en) * | 2022-09-20 | 2024-03-21 | Highlight Therapeutics, S.L. | Novel compositions based on polyinosinic-polycytidylic acid |
WO2024100046A1 (en) * | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024100044A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol |
WO2024100040A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0532525T3 (da) | 1990-05-18 | 1995-12-04 | Genentech Inc | Nye protein-polykationkonjugater |
DE4104186A1 (de) | 1991-02-12 | 1992-08-13 | Genentech Inc | Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe |
IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
DE19726186A1 (de) | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
KR100644172B1 (ko) | 1998-05-25 | 2006-11-10 | 니뽄 신야쿠 가부시키가이샤 | 핵산 함유 복합체 제제의 제조 방법 |
US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
US20040043030A1 (en) | 2001-07-31 | 2004-03-04 | Immunomedics, Inc. | Polymeric delivery systems |
GB0119346D0 (en) | 2001-08-08 | 2001-10-03 | Bioclones Proprietary Ltd | Process for the maturation of dendritic cells |
AU2002365360A1 (en) | 2001-11-28 | 2003-06-10 | Biopolymed Inc. | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
AU2002236324A1 (en) | 2002-02-28 | 2003-09-09 | Jong Sang Park | Cationic highly branched polyaminoester |
WO2004013310A2 (en) | 2002-08-06 | 2004-02-12 | Intradigm Corporation | Methods of down regulating target gene expression in vivo by introduction of interfering rna |
US7927792B2 (en) | 2002-11-18 | 2011-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Targeted double stranded RNA mediated cell killing |
US8969543B2 (en) | 2003-04-03 | 2015-03-03 | Bioneer Corporation | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
AU2003219576A1 (en) | 2003-04-03 | 2004-10-25 | Korea Advanced Institute Of Science And Technology | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
US20050118718A1 (en) | 2003-09-22 | 2005-06-02 | University Of Utah Research Foundation | Stabilization and controlled delivery of ionic biopharmaceuticals |
WO2005090570A1 (en) | 2004-03-24 | 2005-09-29 | Supratek Pharma Inc. | Therapeutic compositions and methods for treating diseases that involve angiogenesis |
WO2006054129A1 (en) | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
US7893244B2 (en) | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
CN101287500A (zh) * | 2005-08-19 | 2008-10-15 | 恩多塞特公司 | 多药物配体缀合物 |
US20090011004A1 (en) | 2005-12-30 | 2009-01-08 | Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine | Improved carriers for delivery of nucleic acid agents to cells and tissues |
WO2007084797A1 (en) | 2006-01-23 | 2007-07-26 | Abbott Laboratories | Chemically modified polycation polymer for sirna delivery |
US20070225213A1 (en) | 2006-03-23 | 2007-09-27 | Kosak Matthew K | Nucleic acid carriers for delivery of therapeutic agents |
JP2009534309A (ja) | 2006-03-31 | 2009-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | 治療剤の標的化送達のためのシステム |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
ES2376175T3 (es) | 2007-09-28 | 2012-03-09 | Bind Biosciences, Inc. | Direccionamiento a células de c�?ncer usando nanopart�?culas. |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US20110027172A1 (en) | 2007-12-10 | 2011-02-03 | Zhuang Wang | Drug delivery system for pharmaceuticals and radiation |
EP2247308A4 (en) | 2008-01-10 | 2012-04-18 | Nventa Biopharmaceuticals Corp | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND CATIONIC POLYMER |
WO2009131435A1 (en) | 2008-04-23 | 2009-10-29 | Erasmus University Medical Center Rotterdam | Linker containing bungarotoxin and a binding peptide |
EP2113257A1 (en) | 2008-04-30 | 2009-11-04 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer |
EP2123304A1 (en) | 2008-05-23 | 2009-11-25 | Freie Universität Berlin | Compounds suited as nanocarriers for active agents and their use |
WO2009151539A1 (en) | 2008-05-24 | 2009-12-17 | Sirnaomics, Inc. | COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS |
HUE035770T2 (en) | 2008-06-16 | 2018-05-28 | Pfizer | Process for the preparation of diblock copolymers functionalized with targeting material for use in the preparation of therapeutic nanoparticles |
MX2011006720A (es) * | 2008-12-22 | 2011-10-06 | Yissum Res Dev Co | Vector de acido ribonucleico de cadena doble buscador del receptor del factor de crecimiento epidermico para el tratamiento sistemico del cancer. |
WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
US20100266642A1 (en) | 2009-02-20 | 2010-10-21 | Bind Biosciences, Inc. | Modified cells for targeted cell trafficking and uses thereof |
US9603919B2 (en) | 2009-03-31 | 2017-03-28 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
ES2368963B1 (es) | 2009-07-04 | 2012-10-10 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado. |
CN101638484A (zh) * | 2009-08-24 | 2010-02-03 | 中国科学院长春应用化学研究所 | 聚乙二醇单甲醚-聚2-甲基-2-羧基碳酸丙烯酯接枝聚乙烯亚胺共聚物与制法及应用 |
EP2509629A4 (en) | 2009-12-09 | 2013-06-26 | Ibc Pharmaceuticals Inc | DNL ("DOCK-AND-LOCK") COMPLEXES FOR INTERFERING RNA ADMINISTRATION |
US9295649B2 (en) | 2009-12-15 | 2016-03-29 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
WO2011084521A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same |
EA201290497A1 (ru) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых |
JP6137834B2 (ja) | 2010-02-24 | 2017-05-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | siRNAの標的化送達のための組成物 |
WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
WO2011130577A1 (en) | 2010-04-14 | 2011-10-20 | Intezyne Technologies, Incorporated | Controlled polyplex assembly |
EP2395041A1 (en) | 2010-06-10 | 2011-12-14 | F. Hoffmann-La Roche AG | Polymers for delivery of nucleic acids |
WO2011154331A1 (en) | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
WO2012005572A1 (en) | 2010-07-06 | 2012-01-12 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
US20120207795A1 (en) | 2010-07-13 | 2012-08-16 | The Regents Of The University Of California | Cationic polymer coated mesoporous silica nanoparticles and uses thereof |
US20130202652A1 (en) | 2010-07-30 | 2013-08-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
FR2963350B1 (fr) | 2010-07-30 | 2013-11-01 | Univ D Evry Val D Essonne | Nouveaux copolymeres a bloc et leurs utilisations pour delivrer une substance active dans une cellule. |
US8461224B2 (en) | 2011-03-04 | 2013-06-11 | National Health Research Institutes | Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery |
US10029023B2 (en) | 2011-03-31 | 2018-07-24 | The Johns Hopkins University | Theranostic imaging agents and methods of use |
US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
WO2013166004A2 (en) | 2012-05-02 | 2013-11-07 | Novartis Ag | Organic compositions to treat kras-related diseases |
EP2852668B1 (en) | 2012-07-12 | 2016-04-27 | ProQR Therapeutics II B.V. | Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell |
JP2015536319A (ja) | 2012-10-16 | 2015-12-21 | ウィリアム・マーシュ・ライス・ユニバーシティ | 薬剤耐性を克服するための改善されたナノベクターベースの薬物送達システム |
WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
SG10201706618UA (en) | 2012-11-15 | 2017-09-28 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
EP2930180B1 (en) | 2012-12-06 | 2021-11-10 | Kyowa Hakko Bio Co., Ltd. | Double-stranded ribonucleic acid for adjuvants |
KR102285326B1 (ko) | 2013-06-28 | 2021-08-04 | 에트리스 게엠베하 | Rna를 세포에 도입하기 위한 조성물 |
CN104341488A (zh) | 2013-08-02 | 2015-02-11 | 复旦大学 | c(LyP-1)多肽及其构建的纳米递药系统和应用 |
US20160312218A1 (en) | 2013-11-04 | 2016-10-27 | Northeastern University | System for co-delivery of polynucleotides and drugs into protease-expressing cells |
JP2017505104A (ja) | 2013-11-08 | 2017-02-16 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | インビボにおける薬剤送達のための核酸ナノ構造体 |
BR112016021130A2 (pt) | 2014-03-14 | 2017-08-15 | Pfizer | Nanopartículas terapêuticas, composição farmacêutica compreendendo as referidas nanopartículas, processo para a preparação e uso das mesmas |
WO2015144736A1 (en) | 2014-03-24 | 2015-10-01 | Riboxx Gmbh | Double-stranded rna conjugates and their use |
JP7348708B2 (ja) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
RU2771104C2 (ru) * | 2014-05-14 | 2022-04-26 | Таргиммьюн Терапьютикс Аг | Улучшенные полиэтилениминовые полиэтиленгликолевые векторы |
EP3253414A4 (en) | 2015-02-05 | 2018-07-11 | The University Of Queensland | Targeting constructs for delivery of payloads |
US20160331845A1 (en) | 2015-05-14 | 2016-11-17 | The Johns Hopkins University | Compositions of nucleic acid-containing nanoparticles for in vivo delivery |
PT3319587T (pt) | 2015-11-17 | 2019-11-20 | Bioncotech Therapeutics S L | Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina |
-
2015
- 2015-05-14 RU RU2016146389A patent/RU2771104C2/ru active
- 2015-05-14 IL IL287206A patent/IL287206B2/en unknown
- 2015-05-14 KR KR1020167033997A patent/KR102472590B1/ko active IP Right Grant
- 2015-05-14 KR KR1020227041535A patent/KR102589295B1/ko active IP Right Grant
- 2015-05-14 WO PCT/IL2015/050514 patent/WO2015173824A1/en active Application Filing
- 2015-05-14 JP JP2017512466A patent/JP6753843B2/ja active Active
- 2015-05-14 SG SG10201911695SA patent/SG10201911695SA/en unknown
- 2015-05-14 AU AU2015260725A patent/AU2015260725B2/en active Active
- 2015-05-14 CN CN202310954498.4A patent/CN116966310A/zh active Pending
- 2015-05-14 BR BR112016026581A patent/BR112016026581A2/pt active Search and Examination
- 2015-05-14 US US15/310,735 patent/US10278991B2/en active Active
- 2015-05-14 EP EP15793532.1A patent/EP3142673A4/en active Pending
- 2015-05-14 CA CA2949017A patent/CA2949017A1/en active Pending
- 2015-05-14 MX MX2016014881A patent/MX2016014881A/es active IP Right Grant
- 2015-05-14 MA MA039970A patent/MA39970A/fr unknown
- 2015-05-14 CN CN202310955550.8A patent/CN116966311A/zh active Pending
- 2015-05-14 NZ NZ727092A patent/NZ727092A/en unknown
- 2015-05-14 CN CN201580025099.3A patent/CN106687121A/zh active Pending
- 2015-05-14 SG SG11201609442YA patent/SG11201609442YA/en unknown
-
2016
- 2016-11-10 IL IL248890A patent/IL248890B/en unknown
- 2016-11-11 PH PH12016502258A patent/PH12016502258A1/en unknown
- 2016-11-14 MX MX2020012698A patent/MX2020012698A/es unknown
- 2016-11-21 ZA ZA2016/08042A patent/ZA201608042B/en unknown
-
2019
- 2019-03-07 US US16/296,117 patent/US11298376B2/en active Active
- 2019-03-08 US US16/297,133 patent/US10543232B2/en active Active
-
2020
- 2020-08-20 JP JP2020139643A patent/JP7406475B2/ja active Active
-
2021
- 2021-05-24 AU AU2021203336A patent/AU2021203336A1/en active Pending
-
2022
- 2022-03-02 US US17/653,221 patent/US20220339189A1/en active Pending
-
2023
- 2023-12-15 JP JP2023211790A patent/JP2024028995A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016026581A2 (pt) | vetores de polietilenoimina polietilenoglicol melhorados | |
BR112018002033A2 (pt) | ligantes covalentes em conjugados de anticorpo-fármaco e métodos para fabricação e uso dos mes-mos | |
AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
CY1124437T1 (el) | Ανθρωπινα αντισωματα κατα toy pd-l1 | |
CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
CY1123274T1 (el) | Αντισωματα εναντι-οχ40 και χρησεις αυτων | |
WO2017031458A3 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
GT201700102A (es) | Conjugados de anticuerpo-fármaco | |
CL2017001154A1 (es) | Moléculas de unión específicas para cd73 y usos de las mismas | |
CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
EP3344263A4 (en) | CANCER ANTIQUES AND USES THEREOF | |
BR112018069507A2 (pt) | agentes de alta afinidade alvejados por antígeno de membrana específica da próstata para endoradioterapia de câncer de próstata | |
PH12016501411A1 (en) | Bifunctional cytotoxic agents | |
BR112018002432A2 (pt) | anticorpos de ligação à il-8 e usos dos mesmos | |
ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
WO2015197598A3 (en) | Multispecific antigen binding proteins | |
CL2016002667A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
UY36075A (es) | Derivados de tubulisina | |
CL2017000506A1 (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
EP3334500A4 (en) | MULTILIGAND-ACTIVE CONJUGATES AND USES THEREOF | |
BR112016029207A2 (pt) | resinas de polietileno | |
CY1123743T1 (el) | Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου | |
CY1123019T1 (el) | Σπειροκυκλικες ενωσεις |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: TARGIMMUNE THERAPEUTICS AG (CH) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: TARGIMMUNE THERAPEUTICS AG (CH) |